Breast Cancer Clinical Trials & Research at St. Joseph Health Medical Group
In the U.S., breast cancer is the second most common cancer in women after
skin cancer. It can occur in both men and women. The most common type
of breast cancer is ductal carcinoma, which begins in the cells of the
ducts. Breast cancer can also begin in the cells of the lobules and in
other tissues in the breast. Invasive breast cancer is breast cancer that
has spread from where it began in the ducts or lobules to surrounding tissue.
St. Joseph Health Medical Group is currently enrolling patients for the
following breast cancer clinical trials:
Randomized phase III trial evaluating the role of weight loss in adjuvant
treatment of overweight and obese women with early breast cancer (NCI BWEL)
Treatment agent: Health education program +/- weight loss intervention
PI:
Ian Anderson, MD
Study Coordinator: Camille Shaffer //
Camille.Shaffer@stjoe.org // (707) 521-3809
Resources and Links:
clinicaltrials.gov NCT No: NCT02750826
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus
a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with
HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic
Breast Cancer Previously Treated with a Taxane (JIT Odonate)
Treatment agent: Tesetaxel +/- capecitabine
PI:
Ian Anderson, MD
Study Coordinator: Kim Young //
Kimberly.Young@stjoe.org // (707) 521-3814
Resources and Links:
clinicaltrials.gov NCT No: NCT03326674
A Phase I/IIa Study of the SV-BR-1-GM Regimen in Metastatic or Locally
Recurrent Breast Cancer Patients in Combination with Pembrolizumab (BriaCell
Rollover)
Treatment agent: SV-BR-1-GM + Pembrolizumab
PI:
Jarrod Holmes, MD
Study Coordinator: Sabine Ucik //
Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links:
clinicaltrials.gov NCT No: NCT03328026
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab
After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple
Negative Breast Cancer (TNBC) (MK- 7339-009/Keylynk-009)
Treatment agent: Olaparib + Pembrolizumab
PI:
Ian Anderson, MD
Study Coordinator: Teresa
Resources and Links:
clinicaltrials.gov NCT No: NCT04191135